Abstract. Alteration of mitochondria-associated membranes (MAMs) has been proposed to contribute to the pathogenesis of Alzheimer's disease (AD). We studied herein the subcellular distribution, the processing, and the protein interactome of the amyloid-␤ protein precursor (A␤PP) and its proteolytic products in MAMs. We reveal that A␤PP and its catabolites are present in MAMs in cellular models overexpressing wild type A␤PP or A␤PP harboring the double Swedish or London familial AD mutations, and in brains of transgenic mice model of AD. Furthermore, we evidenced that both ␤-and ␥-secretases are present and harbor A␤PP processing activities in MAMs. Interestingly, cells overexpressing APP swe show increased ER-mitochondria contact sites. We also document increased neutral lipid accumulation linked to A␤ production and reversed by inhibiting ␤-or ␥-secretases. Using a proteomic approach, we show that A␤PP and its catabolites interact with key proteins of MAMs controlling mitochondria and ER functions. These data highlight the role of A␤PP processing and proteomic interactome in MAMs deregulation taking place in AD.
INTRODUCTION
Alzheimer's disease (AD) is a devastating neurodegenerative pathology characterized by the 1550 
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C-terminal fragment (CTF) of 99 amino acids (C99), and by the ␥-secretase releasing A␤ peptide, and the APP intracellular domain (AICD) [2] . Cleavage of A␤PP by ␣-secretase precludes the formation of A␤ peptides and leads to the generation of another CTF of 83 amino acids (C83) [3, 4] .
A␤ peptides are generated extracellularly, but also within intracellular organelles such as the endoplasmic reticulum (ER) and mitochondria. A␤PP is folded and modified in the ER and transported through the Golgi complex to the plasma membrane. It was proposed that A␤ is generated in the ER lumen as a result of deficits in axonal transport [5] . A␤ oligomers (considered to be the most toxic forms of A␤) accumulate in the ER in hippocampal neurons and thereby, likely lead to cell death in transgenic mice expressing A␤PP mutant [6] . Association of A␤PP with mitochondria was also reported by several groups [7] [8] [9] . A␤ was shown to accumulate into mitochondria prior to extracellular plaques and in a time-dependent manner, leading to mitochondrial damage [10] [11] [12] . In addition, different components of the ␥-secretase complex have been located in different subcellular compartments, including the ER and mitochondria [9, [13] [14] [15] [16] .
Physical association between the ER and mitochondria, also known as mitochondria-associated membranes (MAMs), play important roles in various cellular housekeeping functions such as phospholipids-, glucose-, cholesterol-, and fattyacid-metabolism, as well as calcium signaling [17, 18] . The hypothesis stating that AD could be a disorder linked to MAMs alterations started to emerge only in the last 6 years [19] [20] [21] . In this study, we show that A␤PP and its catabolites accumulate in MAMs and increase ER-mitochondria contact sites. We also evidence that both ␤-secretase and ␥-secretase complex are present and may harbor enzymatic activities in MAMs. Of most importance, we document increased neutral lipid accumulation in cellular models of AD, which was reversed by inhibiting ␤-or ␥-secretases. A proteomic approach revealed the protein interactome of A␤PP and its catabolites with key proteins of MAMs controlling mitochondria and ER functions.
MATERIAL AND METHODS

Cells
Human SH-SY5Y neuroblastoma cells (CRL-2266, ATCC) stably expressing pcDNA3.1 (control), wild type human A␤PP (APPwt), or human A␤PP harboring the double Swedish mutations (APP swe : APPKM670/671NL) constructs were generated as already described [22] . Polyclonal stable lines were maintained in DMEM containing 10% FBS in the presence of 400 g geneticin (Gibco).
Mock-transfected or APP695 LDN -expressing CHO cells were obtained by stable transfection of pcDNA4 empty vector (Control), wild type hAPP695 cDNA or harboring the London mutation (APP LDN : APPV642I) and subcloned in pcDNA 4 vector. Single clones were maintained in DMEM containing 10% FBS, sodium hypoxanthine-thymidine supplement, and 300 M proline as already described [23] .
Cells were treated overnight (20 h) with ␤-or ␥-secretase inhibitors. ␥-secretase inhibitor ELND006 was used at 5 M final concentration and vehicle (methylcellulose/polysorbate 80; Sigma-Aldrich) was used as control [24, 25] . ␤-secretase inhibitor (Eli Lilly's inhibitor LY288672 [26] , synthesized by Elan Pharmaceutical) was used at 30 M final concentration prepared in DMSO. Vehicle was used as control since no difference was observed as compared to cells treated with DMSO.
Mice
We used brains isolated from doubletransgenic APP 23 xPS 45 mice (B6-Tg hAPP751 K670 N/M671 L × PS1 G384A mThy1). These mice were obtained through Material Transfer Management from Novartis. To generate APP 23 xPS 45 mice, we crossed APP 23 transgenic line overexpressing hA␤PP with the Swedish double mutation at positions 670/671 [hAPP751: K670 N/M671L], with PS 45 transgenic line overexpressing human PS1 carrying G384A mutation [hPS1: G384A] [27] . Both lines are driven by a Thy-1 promoter and were developed in C57BL/6 genetic background. Control wild type (WT) mice were from the same genetic background.
Ethics statements
In vivo experiments were performed in accordance with relevant guidelines and regulations established by the European community council (Directive of November 24, 1986) , and approved by Nice University Animal care and use Committee, and the National Council on animal care of the Ministry of Health (Project n • : NCE/2013-152). Mice were housed in SPF animal facility.
Cellular fractionation
Cell fractionation was performed using SH-SY5Y and CHO cell lines, and brains dissected from WT, APP 23 , PS 45 , and APP 23 xPS 45 mice using an optimized protocol to isolate subcellular fractions from tissues and cells [28] . Cells (≈10 9 ) were harvested, washed by centrifugation at 500 × g for 5 min with PBS. Cells or brains (n = 5 for each mice group) were resuspended in homogenization buffer (225 mM mannitol, 75 mM sucrose, 30 mM Tris-HCl pH 7.4, 0.1 mM EGTA) and gently disrupted by Dounce homogenization at 4 • C. The homogenate was centrifuged twice at 600 × g for 5 min to remove nuclei and unbroken cells, and then the supernatant was centrifuged at 10 300 × g for 10 min to pellet crude mitochondria (Mc). The resultant supernatant was centrifuged at 20 000 × g for 30 min at 4 • C. The pellet consists of lysosomal and plasma membrane fractions. Further centrifugation of the obtained supernatant at 100 000 × g for 90 min (70-Ti rotor; Beckman, France) at 4 • C results in the isolation of ER (pellet) and cytosolic fraction (supernatant). The crude mitochondrial (Mc) fraction, resuspended in MAM isolation buffer (250 mM mannitol, 5 mM HEPES pH 7.4 and 0.5 mM EGTA), was subjected to Percoll gradient centrifugation (Percoll medium: 225 mM mannitol, 25 mM HEPES pH 7.4, 1 mM EGTA, and 30% vol/vol Percoll) in a 10-ml polycarbonate ultracentrifuge tube. After centrifugation at 95,000 × g for 30 min (SW40 rotor; Beckman, France), a dense band containing purified mitochondria (Mp) was recovered approximately 3/4 down of the tube, resuspended in MAM isolation buffer and washed by centrifugation at 6300 × g for 10 min to remove the Percoll and finally resuspended in small volume of MAM isolation buffer. The MAMs, containing the structural contacts between mitochondria and ER, collected from the Percoll gradient as a diffuse white band located above the mitochondria, were diluted in MAM isolation buffer and centrifuged at 6300 × g for 10 min; then the supernatant was further centrifuged at 100 000 × g for 90 min (70-Ti rotor, Beckman) to pellet the MAMs fraction.
SDS-PAGE analysis
To detect A␤ peptide, protein extracts (40 g) were incubated with 70% formic acid (Sigma) and Speed Vac evaporated for 40 min. The pellets were dissolved in 1 M Tris pH 10.8, 25 mM Betaine and diluted in 2x Tris-Tricine loading buffer (125 mM Tris-HCl pH 8.45, 2% SDS, 20% Glycerol, 0.001% Bromophenol blue, and 5% ␤-mercaptoethanol). Proteins were resolved by 16.5% Tris-Tricine SDS-PAGE, transferred onto PVDF membranes, and incubated overnight with specific antibodies as specified in legends. All the other proteins were resolved by Tris-Glycine SDS-PAGE following standard procedures.
Antibodies
A␤, C99, and full length A␤PP were detected using 6E10 antibody (Covance) recognizing 1-16 residues of A␤. A␤PP C-terminal fragments (A␤PP CTF: C99 and C83), were detected using A␤PP C-terminal antibody (Sigma Aldrich) recognizing 676-695 residues of A␤PP. Other antibodies directed toward the following proteins were as follow: Cytochrome C oxidase subunit II (Cox), and RyR (Thermo scientific); VDAC-1 (Calbiochem); HSP60, Calreticulin, and GRP75 (Santa Cruz); Chapronin 10 (Stressgen, Biotech); Nicastrin, Tom20, ␣-Tubulin, and ␤-Actin (Sigma Aldrich), SERCA2b (clone IID8), and Aph1 (Thermo Scientific Pierce Products); BACE-1 and Cytp450 (Abcam); PS1-Nter is a generous gift from Gopal Thinakaran.
Detection of Aβ by ELISA
The concentrations of A␤ 40 and A␤ 42 were measured in subcellular fractions by using the respective ELISA kits (Invitrogen) following the manufacturer's instructions. Briefly, 40 g of each fraction was treated with 5 M guanidine, 50 mM HCl solution for 3-4 h at room temperature and stored at -20 • C overnight. Supernatant obtained after centrifugation at 16,000 rpm for 20 min at 4 • C, were diluted at >1/10 in D-PBS-BSA 5% and used for ELISA.
In vitro α-secretase assay ␣-secretase activity was monitored as already described [29] . Briefly, 20 g of each subcellular fraction were incubated in 90 l final volume of Tris buffer (10 mM, pH 7.5) containing ␣-secretase substrate (JMV2770, 100 M) in the absence or presence of the metal chelator o-phenanthroline (100 M) reported to block metalloproteases. ␣-secretase activity corresponds to the ␣-secretase inhibitor-sensitive fluorescence recorded at 320 and 420 nm as excitation and emission wavelengths, respectively.
In vitro β-secretase assay ␤-secretase activity was monitored as already described [22] . Briefly, 20 g of each subcellular fraction were incubated in a final volume of acetate buffer (25 mM, pH4.5, 100 l) containing BACE-1 substrate [(7-methoxycoumarin-4-yl)-acetyl-SEVNLDAEFRK (2,4-dinitrophenyl)-RRNH 2 ; 10 m; R&D Systems] in the absence or presence of ␤-secretase inhibitor I (50 m; PromoCell). BACE-1 activity corresponds to the ␤-secretase inhibitor I-sensitive fluorescence recorded at 320 and 420 nm as excitation and emission wavelengths, respectively.
In vitro γ-secretase assay
In vitro ␥-secretase assay was assessed as already described [30] . Twenty g of each subcellular fraction were resuspended in solubilization buffer (150 mM sodium citrate pH6.4 containing 3-[(3-cholamydopropyl) dimethylammonio]-2-hydroxy-1-propanesulfonate 1% (v/v)) supplemented with protease inhibitor mixture. All steps were performed at 4 • C. Solubilized membranes were diluted once with sodium citrate buffer (150 mM pH 6.4), and with reaction buffer (150 mM sodium citrate pH 6.4, 20 mM dithiothreitol, 0.2 mg/ml BSA, 1 mg/ml egg phosphatidyl choline and 50 g/mL recombinant C100-FLAG). The resulting reaction mix were then either incubated over constant agitation for 16 h at 37 • C or stored at 4 • C (negative controls). Samples were then supplemented with 2x Tris-Tricine loading buffer, boiled for 5 min and subjected to 16.5% Tris-Tricine SDS-PAGE.
Immunofluorescence analysis
Cells grown on 25 mm round coverslips were fixed in PFA 4% solution for 10 min at room temperature. Cells were permeabilized with triton 0.5%, and nonspecific binding sites were blocked for 1 h with BSA (5%). Cells were then incubated at 4 • C overnight with primary antibodies diluted in BSA (5%). After 3 washes, coverslips were incubated with secondary antibodies [fluorescent Alexa Fluor antibodies, Alexa 488-and Alexa 594-or Alexa 633-conjugated (Invitrogen; 1:1000)] at room temperature during 1 h. Immunofluorescence images were acquired on Leica SP5 confocal microscope using excitation filters 488, 594, and 633 nm. Images were analyzed using ImageJ.
High resolution imaging
To visualize mitochondria and ER organelle colocalization, we used GFP construct specifically targeted to the ER. Mitochondria were labeled by using 10 nM Mitotraker ® Deep Red dye. Z-series images acquired on Leica SP5 microscope were deconvolved. ER and mitochondria colocalization was calculated as the number of voxels (volume pixels) occupied by both signals (i.e., erGFP and Mitotraker Deep Red) over all voxels occupied by the mitochondria (i.e. Mitotraker ® Deep Red signal) in thresholded images [31] . The spectral proprieties of these two fluorochromes allow specific identification of the two compartments and quantification of contact sites.
Electron microscopy
Cells were fixed in situ with 2.5% glutaraldehyde in 0.1 M phosphate buffer at room temperature (RT) for 20 min. Samples were rinsed and then post-fixed with 1% osmium tetroxide and 1% potassium ferrocyanide in 0.1 M cacodylate buffer for 1 h at RT to enhance the staining of cytoplasmic membranes. Cells were rinsed with distilled water, embedded in epoxy resin, sectioned, and examined with a Philips CM12 transmission electron microscope equipped with an Olympus SIS CCD camera. Images were acquired randomly by a blinded investigator. We counted the total number of mitochondria (n > 150) in contact or not with ER in more than 10 different micrographs obtained from two different experiments. Data are presented as a percentage of mitochondria in contact with ER.
Neutral lipid staining
Cells grown on 25 mm round coverslips were fixed in PFA 4% solution for 20 min at room temperature. Fixed cells were gently rinsed with PBS 3 times to remove residual formaldehyde. Cells were stained with 1X LipidTOX™ prepared in PBS for 30 min at room temperature. Coverslips were then processed for image acquisition on Leica SP5 confocal microscope using excitation filters 488. Images were thresholded, converted to mask and analyzed using Particle analysis ImageJ plugin.
Oligomeric Aβ preparation
Human synthetic A␤ (Bachem AG, Switzerland) was suspended in hexafluoroisopropanol, HFIP; Sigma-Aldrich) to 1 mM. Peptide samples were vortexed to obtain a homogenous solution, aliquoted into microfuge tubes, and lyophilized overnight under the hood. The A␤ peptide films were stored desiccated at -20 • C until further processed. To form A␤ oligomers, peptide films were resuspended to 5 mM in DMSO, diluted in ice cold PBS. Aggregation was allowed to proceed for 24 h at 4 • C before the peptide solution was centrifuged at 14000 × g for 10 min at 4 • C. Supernatant containing oligomeric A␤ was then used at ≈5 M.
Immunoprecipitation and in-gel digestion
After preclearing with protein A-agarose (SigmaAldrich) (1 h, 4 • C), MAM fractions (40 g) isolated from control CHO cells and overexpressing APP LDN were immunoprecipitated using 6E10 antibody (5 g). Immunoprecipitates were recovered by overnight incubation at 4 • C, and then incubated with protein A-agarose for 3 h at 4 • C. Beads were washed three times with CHRIS buffer (50 mM Tris pH 8, 10% glycerol, 200 mM NaCl, 0.5% Nonidet p-40, and 0.1 mM EDTA) supplemented with protease inhibitors (Complete, Roche diagnostics) and once with PBS. Beads were then resupended in Laemli 2x buffer, heated at 95 • C, and then run on Tris-Glycine PAGE. Gels were stained using Imperial Protein Stain (Thermo scientific), a ready-to-use colorimetric stain formulated with Coomassie dye.
Gel pieces containing proteins were excised and distained by adding 100 L of H 2 O/ACN solvent (1/1). After 10 min incubation with vortexing the liquid was discarded. This procedure was repeated 2 times. Gel piece were then rinsed (15 min) with acetonitrile and dried under vacuum. Gel pieces were reswelled in 50 L of 20 mM dithiothreitol (DTT) in NH 4 HCO 3 100 mM, incubated for 30 min at 56 • C, and next cooled down to RT. The DTT solution was replaced with 50 L of 55 mM of iodoacetamide in 100 mM of NH 4 HCO 3 . After 15 min incubation in the dark at room temperature, the solution was discarded and gel pieces were washed by adding successively i) 100 L of H 2 O/ACN (1/1), repeated 2 times and ii) 100 L of acetonitrile. Next gel pieces were reswelled in 50 L of 50 mM NH 4 HCO 3 buffer containing 10 ng/L of trypsin (modified porcine trypsin sequence grade, Promega) incubated for 1 h at 4 • C. Then the solution was removed and replaced by 50 L of 50 mM NH 4 HCO 3 buffer (without trypsin), and incubated 18 h at 37 • C. After trypsin digestion the solution was transferred into an Eppendorf tube and tryptic peptides were extracted with i) 50 L of 1% AF (acid formic) in water (10 min at RT) and ii) 50 L acetonitrile (10 min at RT). Peptides extracts were pooled, concentrated under vacuum and solubilized in 15 L of 0.1% TFA (trifluoroacetic acid) in water.
NanoHPLC-MALDI-TOF/TOF analysis
Peptide separation was carried out using a nanoHPLC offline (ultimate 3000, Thermo Fisher Scientific) coupled with a MALDI-TOF/TOF mass spectrometer (4800 plus, Applied Biosystems). Peptides solution was concentrated on a -Precolumn Cartridge Acclaim PepMap 100 C 18 For offline nanoHPLC-MALDI-TOF/TOF-MS and MS/MS analyses, fractions were collected on an Opti-TOF LC/MALDI target (123 × 81 mm, Applied Biosystems) and fractionation was done using the Probot fractionation robot (DIONEX, LC Packings). Matrix solution (␣-cyano-4-hydroxycinnamic acid, 2.5 mg/mL in 50% water, 50% acetonitrile, 0.1% TFA solution) and nanoHPLC fractions were mixed (in rate 4:1, matrix:fractions) and collected every 20 s (208 fractions were collected per run).
MS spectra were recorded automatically in a mass range of 700-4000 Da resulting from 200 laser shots of constant intensity. Data were collected using 4000 series Explorer (Applied Biosystems) allowing for an automatic selection of peptide masses for subsequent MS/MS experiments. Each MS/MS spectra acquired using 1000 laser shots were further processed using 4000 series Explorer. Finally all raw data were transferred into ProteinPilot software (Applied Biosystems, MDS Analytical Technologies) and proteins identification was processed using Paragon TM Algorithm. Our analyses took in consideration only peptides with confidence index 95%. This experiment was done twice.
Statistical analyses
Results are reported from at least three different experiments or as indicated. Statistical analyses were done using Student's t-test, or ANOVA one-way and Tukey post-test or Newman-Keuls Multicomparison post-test. p value <0.05 was considered significant.
RESULTS
AβPP and its proteolytic products are present in MAMs fraction of in vitro and in vivo study models of AD
We first aimed at establishing by subcellular fractionation, the distribution of A␤PP and its proteolytic catabolites in human SH-SY5Y neuroblastoma cells stably expressing pcDNA3.1 (control) or human A␤PP harboring the double Swedish mutations (APP swe : APPKM670/671NL) constructs. We already reported that SH-SY5Y cells expressing APP swe harbor increased A␤PP processing yielding the production of A␤PP CTFs fragments (C99 and C83) and of A␤ peptides [22] .
We investigated the presence of A␤PP and its proteolytic catabolites in MAMs. Although several techniques are available to isolate mitochondria, only few are specifically tuned to the isolation of MAMs, containing unique regions of ER membranes attached to the outer mitochondrial membrane and mitochondria without contamination from other organelles (i.e., pure mitochondria). We used an optimized protocol to isolate these fractions from tissues and cells [28] . Subcellular fractionation procedure was validated by confirming the expression of different proteins in cellular compartments where they were known to be enriched, namely in the ER (SERCA2b, calreticulin (CRT)), in mitochondria (cytochrome oxidase subunit II (Cox), and voltage dependent anion channel 1 (VDAC1)), and in MAMs (Glucose regulated protein 75 (GRP75)) (Fig. 1A,  B) . Fraction enrichment was further demonstrated by the loss of actin signal in pure mitochondria (Mp), ER, and MAMS fractions (Fig. 1A, B) . We observed A␤PP and A␤ expressions in the whole homogenate (homog), in crude mitochondria (Mc), in pure mitochondria (Mp), and in ER fractions (Fig. 1B) . Interestingly, we noticed the presence of full-length A␤PP and of A␤ in MAMs fraction of APP swe expressing cells (Fig. 1B) . Full-length A␤PP was also observed in MAMs fraction of control cells, thus indicating that both endogenous and overexpressed A␤PP are present in MAMs. However, only a slight A␤ signal was noticed in control cells. This may be related to low expression level of A␤PP in control cells.
We then investigated A␤PP subcellular localization in a second cellular model expressing the London APP mutation (APP LDN : APPV642I). In fact, while the Swedish mutation increases the rate of ␤-cleavage and is proposed to alter the trafficking of A␤PP [32] , the "London" mutation increases the relative amount of the more toxic A␤ 42 produced by ␥-cleavage, but is not proposed to alter trafficking [33] ; Furthermore, It was already reported that CHO cells expressing APP LDN yield high levels of intracellular and secreted A␤ oligomers [23, 34] , and several lines of evidence concord to demonstrate that at least part of the AD-related neurodegenerative process could be due to A␤ oligomers [34] . Thus, we carried out similar analyses on control and APP LDN cells (Supplementary Figure 1A) . We revealed the presence of full length A␤PP, and its C-terminal fragments (C99 and C83), and of A␤ in the whole homogenate, and in Figure 1A) . In this model, we also observed the presence of full-length A␤PP in MAMs fraction of control cells. These first set of data show that A␤PP, CTFs, and A␤ are present in MAMs in two in vitro models of AD.
We then examined whether A␤PP and A␤ could also be present in MAMs, in vivo. We measured expressions of A␤PP and its catabolites C99, C83, and A␤ in subcellular fractions prepared from brains isolated from WT and transgenic mice expressing human A␤PP harboring the double Swedish mutations (APP swe : APP 23 ), human presenilin 1 (PS1) (component of the ␥-secretase complex) mutation (PS 45 : G384A), or both (APP 23 xPS 45 ). Cytochrome p450 (Cytp450, an ER resident protein (Fig. 1A) was indeed enriched in the ER fraction (Fig. 1C) . Chapronin 10 (Cpn10), a mitochondrial protein (Fig. 1A) was detected in the homogenate and Mc, and largely enriched in Mp fraction (Fig. 1C) . Both APP 23 and APP 23 xPS 45 showed A␤PP, its C-terminal fragments (C99 and C83), and A␤ expression in MAMs fraction (Fig. 1C) . Interestingly, we also noticed the presence of C83 but to a lesser extent than 45 , APP 23 , and APP 23 xPS 45 transgenic mice. We load 40 g (B) or 20 g (C) of total homogenate (homog), Crude mitochondria (Mc), pure mitochondria (Mp), the endoplasmic reticulum (ER), and MAMs fractions. A␤PP, C99, and A␤ were detected by 6E10 antibody. A␤PP C-terminal fragments (C99 and C83) were detected by A␤PP C-ter antibody. SERCA2b, calreticulin (CRT), and Cytochrome p450 (Cytp450) were used as loading controls for ER fraction. Cox, VDAC1, and Chapronin 10 (Cpn10) were used as loading controls for Mc and Mp fractions. GRP75 was used as loading controls for MAMs fraction. Actin and Tubulin were used as loading controls. Data are representative of 3 independent experiments for (B), and were obtained from 5 animals per group of mice and repeated twice for (C). D) ELISA of A␤ 40 and A␤ 42 done on subcellular fractions isolated from APP 23 transgenic mice. Graph represents Mean ± S.E.M from three experiments and expressed in pg per g of proteins. *p value <0.05, **p value <0.01, ***p value <0.001 calculated using ANOVA one way and Newman-Keuls Multicomparison post-test.
C99 in WT and PS 45 mice (Fig. 1C) . The increased C99 fragment in APP 23 and APP 23 xPS 45 is likely linked to the overexpression of the Swedish mutation known to increase the rate of ␤-cleavage [32] . Finally specific ELISA approaches allowed unraveling both A␤ and A␤ peptides in MAMs fraction of APP 23 (Fig. 1D) . We also unraveled a slightly elevated A␤ 40 /A␤ 42 ratio in Mc, ER, and MAMs as compared to homogenate and Mp fractions. Overall, this set of data indicates that A␤PP and its catabolites are present in MAMs in vivo (Fig. 1C,  D) in agreement with the in vitro data (Fig. 1B and  Supplementary Figure 1) .
Immunolocalization of AβPP and its catabolites in the ER, mitochondria, and MAMs
We then analyzed subcellular localization of A␤PP and its catabolites by immunofluorescence in SH-SY5Y cells expressing APP swe . We investigated the extent of A␤PP, and its catabolites co-localization with the ER and mitochondria by using A␤PP C-ter antibody (recognizing full length A␤PP, C-terminal fragments (C83 and C99), and A␤PP intracellular domain (AICD)), or 6E10 antibody (recognizing full length A␤PP, C99, and A␤ peptides) concomitantly with specific antibodies recognizing proteins localized in the ER (the ryanodine receptor (RyR) and Cytp450), or in the mitochondria (Tom20 and Cox). Representative images show the co-localization (yellow signal) of A␤PP and its catabolites with both the ER (Fig. 2A, C) , and mitochondria (Fig. 2B,  D) markers. Similar results were obtained in CHO cells expressing APP LDN using A␤PP C-ter antibody (Supplementary Figure 1B, C) .
We then examined A␤PP and its catabolites colocalization within ER-mitochondria contact sites. SH-SY5Y cells expressing APP swe were immunolabeled concomitantly with A␤PP C-ter, Tom20, and the ER-resident protein calreticulin (CRT) antibodies (Fig. 2E) . Merge, high magnificence images (Fig. 2E , merge and inset), and super imposable line scan traces (Fig. 2F ) (corresponding to the red, green, and blue fluorescence signals along the red line in the inset) demonstrate co-localization of A␤PP and CTFs with both ER and mitochondria. These data are in agreement with our data obtained by subcellular fractionation and further support the presence of A␤PP and its metabolites in MAMs in cellular models overexpressing both the Swedish and the London mutations.
Full length A␤PP as revealed by using specific antibody recognizing A␤PP N-terminal epitope (APP N-ter) shows also slight co-localization with the ER (Supplementary Figure 3A) and mitochondria (Supplementary Figure 3B ).
Using immunofluorescence and imaging, we also examined the subcellular distribution of wild type A␤PP in both SH-SY5Y and CHO cells. We show the immunolocalization of WT A␤PP and its metabolites in the ER (colocalization with SERCA2b) (Supplementary Figures 3A and 4A These data strengthen our conclusion regarding the subcellular localization and proteolytic processing of A␤PP in MAMs.
β-and γ-secretases are present and show in vitro activities in MAMs fraction
We next revealed by subcellular fractionation of APP 23 transgenic mice brains the presence of ␤-secretase (BACE-1) and of components of the ␥-secretase complex (PS1, Aph1, and nicastrin) in MAMs (Fig. 3A) . In vitro ␥-secretase activity assay allowed us to reveal the hydrolysis of recombinant C100 fragment at 37 • C and not at 4 • C (used as negative control) that yield A␤ production in the homogenate, Mc, Mp, ER, and MAMs fractions isolated from brains of APP 23 mice (Fig. 3B) . We did not notice a difference in ␥-secretase activity between WT and APP 23 mice (Supplementary Figure 5A) . Similarly, ␥-secretase activity was also observed in MAMs fraction isolated from CHO cells expressing APP LDN (Supplementary Figure 5B) . In agreement with BACE-1 expression in APP 23 MAMs (Fig. 3A) , we detect ␤-secretase activity in MAMs fraction in both WT and APP 23 mice fractions (Fig. 3C) , and in control CHO cells and expressing APP LDN (Supplementary Figure 5C ). Related to the presence of C83 (the ␣-secretase-derived CTF) in vivo (Fig. 1C) , we also measured ␣-secretase activity in subcellular fractions isolated form APP 23 transgenic mice. We indeed could observe in vitro ␣-secretase activity in the homogenate, Mc, ER, and MAMs. However, the in vitro ␣-secretase activity was lower in MAMs as compared to the other fractions (Supplementary Figure 5D ). All over, and according to already published data [9, 13, 16, 20] , we revealed the presence and activity of ␥-secretase in MAMs fraction. We also provide for the first time evidences showing that BACE-1 is present in MAMs fraction and that BACE-1 and ␣-secretase may harbor enzymatic activities in this domain.
Increased ER and mitochondria contacts in SH-SY5Y neuroblastoma APP swe cell model
Increased ER-mitochondria colocalization has been reported in human-derived fibroblasts isolated from familial and sporadic AD patients and in mouse embryonic fibroblasts isolated from either PS1 or PS1 and PS2 knockout mice [21] . This was also observed in cells overexpressing familial AD PS2 mutant [35] . We examined herein ER-mitochondria contact sites in live cells overexpressing APP swe (Fig. 4A) . For live cells imaging, the ER was visualized by transfecting GFP construct targeted to the ER (ER GFP). Mitochondria were labeled by using Mitotracker Deep red dye as already described [31] . We noticed that APP swe expressing cells exhibit a significant increased colocalization of the ER and mitochondria as compared to control cells (evidenced by an increase of mitochondria volume in contact with the ER versus total mitochondria volume) (Fig. 4A) . Accordingly, we also revealed increased mitochondria in contact with the ER by electron microscopy in cells overexpressing APPswe as compared to controls (Fig. 4B ).
These data demonstrate that A␤PP mutation/overexpression and most likely its proteolytic products lead to increased ER-mitochondria contact sites.
The increased ER-mitochondria contacts in SH-SY5Y neuroblastoma APP swe cell model may depend on mitochondrial or ER shape and volume. Supplementary experiments are necessary to fully study this issue.
Overexpression of AβPP familial mutations increases neutral lipids accumulation
MAM have the proprieties of an intracellular lipid raft [21] . This micro-domain is also the site of phospholipid synthesis and transport between the ER and mitochondria [36] . We explored the potential lipid dysfunction in relation with A␤PP and its catabolites presence in the MAM and increased ER and mitochondria contacts. In particular, lipid droplets are found in close proximity with the ER and mitochondria [37, 38] .
We used LipidTox Green TM dye to stain and quantify neutral lipid accumulation (major components of lipid droplets). Whereas the lipidTox stain in control CHO cells reveal few positive droplets, the CHO cells expressing APP LDN contained numerous lipidTox positive droplets (∼2-fold over control cells) (Fig. 5A, B) . Similar results were also observed in SH-SY5Y neuroblastoma cells expressing APP swe as compared to its respective control cells (Supplementary Figure 6A, B) . Importantly, the increase in lipid droplets in CHO cells expressing APP LDN was reversed by inhibition of ␤-or ␥-secretases. As expected, both inhibitors block A␤ production (Supplementary Figure 6C) . However, while the inhibitor of ␤-secretase strongly reduces C99 fragment production, inhibitor of ␥-secretase enhances the accumulation of this fragment (Supplementary Figure 6C) . Based on these results, we may postulate that lipid droplets accumulation in our study models is likely linked to the production of A␤ peptides instead of CTFs.
We further demonstrate the specificity of our data regarding the reduction of neutral lipid accumulation obtained with ␤-and ␥-secretase inhibitors observed in CHO cells expressing the London A␤PP mutant. First, we analyzed neutral lipid accumulation in naïve SH-SY5Y cells upon the application of exogenous oligomeric A␤ (Fig. 5C, 5D ). We could indeed show that the treatment with exogenous oligomeric A␤ leads to increased neutral lipid accumulation (Fig. 5C, D) . However, since our A␤ preparation contains both monomeric and oligomeric forms of A␤ (Fig. 5E) , we cannot conclude whether neutral lipids accumulation is linked to either monomeric or oligomeric A␤ (Fig. 5E) . Second, we analyzed neural lipid accumulation in mouse embryonic fibroblasts (MEF) isolated from wild type (expressing endogenous A␤PP) (WT MEF), or invalidated for A␤PP and its family member APLP2 (referred to as APP-TKO MEF) [39] . We established that knock out of A␤PP did not affect neutral lipid accumulation (Supplementary Figure 6D ). Importantly, we did not notice an effect of both ␤-and ␥-secretase inhibitors neither in WT MEF, nor in APP-TKO MEF cells (Supplementary Figure 6D ).
All over, these data demonstrates that neutral lipid accumulation is likely linked to A␤PP overexpression and processing and to A␤ production.
Protein interactome of AβPP and its catabolites in MAMs
Since we showed that A␤PP is present and is processed in MAMs likely contributing to increased ER-mitochondria contact sites, we hypothesized that A␤PP and its catabolites may thus interact with proteins localized in this micro-domain. We used immunoprecipitation combined to proteomic approach to reveal A␤PP and its catabolites protein interactome in MAMs. By using 6E10 antibody, we expected to immunoprecipitate MAMs proteins interacting directly or indirectly with A␤PP holoprotein, C99, and/or A␤ peptides. To exclude false positives due to adsorption of MAMs proteins with IgG beads, we incubated MAMs fractions isolated from CHO cells expressing pcDNA4 (Control) or APP LDN with IgG beads alone (Supplementary Figure 7) . We validated our experimental procedure by revealing A␤PP peptides (accession number: P12023) in MAMs fraction isolated from APP LDN CHO cells but not in CHO control cells, thus providing a positive control of our experimental protocol (Supplementary Figure 8) .
We specifically immunoprecipitated 135 proteins from CHO APP LDN MAM fraction (obtained in 6E10 immunoprecipitate conditions, but not in samples incubated with IgG beads alone) (Supplementary Figure 7) . In the analyses, we excluded IgG and ribosomal proteins. Among immunoprecipitated proteins from CHO APP LDN MAMs fraction, 39 were also identified in CHO control MAMs fraction. The common proteins identified in both samples may reflect MAMs proteins interacting with full length A␤PP rather than those interacting with C99 and A␤ peptides. Indeed, the amount of A␤PP catabolites was clearly lower in control as compared to APP LDN MAMs fraction (Supplementary Figure 1) .
We analyzed the subcellular localization and biological functions of the 96 unique proteins obtained in CHO APP LDN MAMs fraction by using gene onthology (GO) annotation and UniProt (Universal Protein Resource) database. In this study, we exclude from the analysis proteins showing nuclear, extracellular or microtubule localization. We then determined that 38 proteins are resident in mitochondria (44%); 23 proteins have ER localization (27%), 12 proteins are mainly cytosolic (14%), 7 proteins are found in lysosomes, Golgi apparatus, and endosomes (8%), and 6 proteins are associated with the plasma membrane (7%) (Supplementary Figure 7) . It is important to note that mitochondria and ER comprise 71% of the total immunoprecipitated proteins. However, proteins associated with other organelles should not be discounted as contaminants since the plasma membrane, Golgi apparatus, and lysosomes all have tight association with the ER or mitochondria and may execute fundamental cellular functions in these contact microdomains [40, 41] .
We then analyzed the types of function of the proteins identified. Of most interest, the identified molecular functions (Supplementary Figure 7) are mostly attributable to MAMs functions [41, 42] . We focused on the four most significant biological processes: 1) mitochondrial function and transport (n = 23) (Supplementary Figure 7 and Table 1 ); 2) protein synthesis, maturation, folding, processing, and degradation (n = 18) (Supplementary Figure 7 and Table 2 ); 3) vesicle formation and trafficking (n = 12) (Supplementary Figure 7 and Table 3 ); and 4) fatty-acid metabolism (n = 10) (Supplementary Figure 7 and Table 4 ). The remaining pathways correspond to proteins implicated in mitochondria and ER structure (n = 3), apoptosis (n = 2), cellular signaling (n = 7), and other metabolic pathways (n = 4) (Supplementary Figure 7 and Table 1 ).
Protein interactome related to mitochondrial function
The identified mitochondrial proteins (n = 23) are implicated in mitochondrial respiratory chain complexes (n = 9), mitochondrial transport (n = 6), and mitochondrial metabolism (n = 8) (Supplementary Figure 7 and Table 1 ). Interestingly, 6 out of 10 isolated mitochondrial respiratory chain proteins are components or chaperone proteins of the mitochondrial complex I. We also identified Cytochrome b-c1 complex subunit1 (component of the mitochondrial respiratory chain complex III), and two components of the mitochondrial ATP synthase complex (Supplementary Figure 7 and Table 1 ). The protein interactome of A␤PP and its catabolites related to mitochondrial function include also proteins implicated in mitochondrial metabolism (e.g., Acyl-CoA, and coenzyme Q biosynthesis) ( Table 1 ). In accordance with already reported data, our approach allowed us to identify proteins implicated in mitochondrial transport (e.g., TIM, and TOM complexes) [8, 43, 44] (Supplementary Figure 7 and Table 1 ). This result could be considered as a positive control validating our experimental procedure.
Protein interactome related to protein synthesis, maturation, folding, processing, and degradation
We identified different proteins implicated in ER protein maturation (e.g., glycosylation and signal peptidase complex), protein folding (e.g., inhibition of protein aggregation of misfolded proteins, protein quality control), and protein processing and degradation (e.g., peptidases, proteases) (Supplementary Figure 7 and Table 2 ). The protein interactome includes also chaperone proteins inhibiting the aggregation of misfolded proteins (e.g., the protein disulfide-isomerase A4, the protein disulfide-isomerase A6, and the peptidyl-prolyl cisisomerase FKBP11), or implicated in the ER quality control (e.g., the protein sel-1 homolog 1, and the DnaJ homolog subfamily B member 11). Interestingly, we also identified proteins implicated in mitochondrial protein translation, and the mitochondrial presequence protease involved in the degradation of mitochondrial transit peptides (Supplementary Figure 7 and Table 2 ).
Protein interactome related to vesicle formation and trafficking
In addition to the mitochondria, the ER is associated with different subcellular domains that execute divers function such as vesicular traffic [40] . As a matter of fact, we identified a class of A␤PP protein interactome (n = 12) including proteins implicated in vesicle formation and trafficking (Supplementary Figure 7 and Table 3 ). These include Ras-related family proteins (Rab-10, Rab18, and Rab1b) implicated in ER-Golgi transport and vesicular traffic, and Praf2 (PRAF1 family protein 2) known to interacts with numerous Rab GTPases thus assisting in the packaging of Rab proteins into vesicles for the transport to target compartments [45, 46] . We also revealed other proteins implicated in vesicular transport namely the transmembrane emp24 domain containing proteins (Tmed2, Tmed10, and Tmed1) and Arl8b (an Arf-like GTPase being a critical regulator of cargo delivery to lysosomes). We also revealed in the protein interactome Flotillin 1, known to be a scaffolding protein within caveolar membranes and to interact with lipid rafts [47, 48] .
Protein interactome related to fatty-acid metabolism
We classified a fourth cellular pathway including proteins (n = 10) implicated in fatty-acid metabolism (Supplementary Figure 7 and Table 4 ). This includes proteins implicated in fatty-acid elongation or modification (Hsd17b12, Acot1, Far1), fatty-acid beta-oxidation (Acaa2, Hadhb, and Acad9), sterol and cholesterol biosynthesis (Nsdh1, Cyp51a1, Lss), and sphingolipid metabolism (Sptlc1). Based on GO annotation, these proteins are mostly localized in the ER (Hsd17b12, Nsdhl, Sptlc1, Cyp51a1, and Lss), or in the mitochondria (Acot1, Acaa2, Far1, and Hadhb,and Acad9). Nsdhl may be also localized in lipid droplets (Table 4) .
All over, these analyses identify potential new A␤PP and its catabolites interactors in MAMs. However, a dedicated study is necessary to confirm specific direct or indirect interactions of A␤PP or its catabolites with these proteins and their role in MAMs alteration in AD.
DISCUSSION
We used both biochemical and imaging approaches to demonstrate the presence of A␤PP and its catabolites in MAMs in in vitro and in in vivo AD-like models. It is well established that A␤PP is synthe- sized in the ER [49] . Recent studies reported that A␤PP is also associated with mitochondria in AD affected neurons [50, 51] . This was further supported by the presence of A␤PP catabolites (i.e., A␤, C99, and AICD) in the mitochondria [9, [52] [53] [54] [55] . We report in this study A␤PP localization, and processing in MAMs. These results were obtained in two distinct cellular systems (SH-SY5Y and CHO cells) expressing wild type A␤PP or harboring two different familial mutations (APP swe and APP LDN ) thus demonstrating that the observed presence and processing of WT or mutated A␤PP in MAMs is not linked to a specific cell type and not to a specific familial A␤PP mutation. This may also reveal that the subcellular localization and proteolytic processing of A␤PP in MAMs was not linked to AD familial cases but may also be observed in sporadic cases of AD. These data also suggest that even if trafficking of A␤PP may vary according to the mutation, transit through MAMs compartment where A␤PP undergo cleavage is a common denominator independent of the nature of the A␤PP species. We also revealed the presence and activity of ␣-, ␤-, and ␥-secretases in the MAMs. ␥-secretase was shown to exert its activity in the plasma membrane but also in other intracellular compartments such as the trans-Golgi network, lysososmes, pure mitochondria fraction, and MAMs [16, 20, 56] .
However, it is important to emphasize that even if ␥-secretase complex has been found in mitochondria [16] , the putative generation of intra-mitochondrial A␤ and C99 remains puzzling, given the C-terminusout orientation of A␤PP in the outer mitochondrial membrane [9] . A hypothetical model has been proposed stating that A␤ may be produced at the interface between the ER and mitochondria and then transferred to the mitochondria via the TOM import machinery [9, 44] . Another gap to envision the production of A␤ in mitochondria was the demonstration of the presence of active ␤-secretase (BACE-1) in mitochondria or in MAMs. Importantly, we report herein and for the first time the presence of BACE-1 in crude mitochondria and MAMs fractions. Current knowledge on A␤PP and BACE-1 trafficking indicates that plasma membrane and endosomes are likely the major sites of BACE-1-mediated cleavage of A␤PP [57, 58] . Mature BACE-1 localizes largely within plasma membrane cholesterol-rich lipid rafts [57, 58] , and replacing the BACE-1 transmembrane domain with a glycosylphosphatidylinositol anchor extensively targets BACE-1 to lipid rafts and substantially increases A␤ production [59] . In addition, various types of lipids stimulate BACE-1 activity [60] . Interestingly, a recent study revealed that MAMs behave as a detergent-resistant lipid raft-like domain, consistent with the presence and activity of ␤-and ␥-secretase in rafts [21, [61] [62] [63] . In accordance with the presence of ␣-CTF fragment in MAMs, we also could measure an in vitro ␣-secretase activity in this compartment in mice brains (Supplementary Figure 5D) . Other experiments are still needed to further characterize expression and subcellular distribution and trafficking of ␣-secretase in vitro and in vivo. We must take into account that both ␤-and ␥-secretases harbor optimal activities in acidic compartments and that the pH of the ER is almost neutral (pH 7.2), and that of mitochondria matrix is markedly alkaline (pH 8) [64] . Thus, it remains not clear how these enzymes may function in the ER, mitochondria, and MAMs compartments in intact cells. One may postulate that A␤PP, or at least its C-terminal fragments (C99/C83), and BACE-1 are transported to the ER-mitochondria contact sites through a mechanism implicating retrograde vesicular trafficking. Indeed, we identified different proteins related to vesicle formation and trafficking in the protein interactome data of MAMs fraction isolated from CHO cells expressing APP LDN (Table 3) . Dedicated experiments are necessary to confirm this hypothesis and to further explore the molecular mechanisms underlying BACE-1 localization and in situ function in MAMs.
We report an increased ER-mitochondria contact sites in SH-SY5Y cells overexpressing APP swe . Accordingly, an increased ER-mitochondria connectivity was detected in human fibroblasts isolated from individuals with familial AD mutations as well as sporadic AD cases, and in MEFs isolated from mice simple or double knockout for PS1 or PS2 [21] . Similar results were obtained in neuroblastoma cells expressing familial AD-linked PS2 mutations [35] . Interestingly, increased ER-mitochondria connectivity was also reported in a transgenic AD mouse model expressing mutant tau protein [65] , and most recently, in cells exposed to apolipoprotein E (ApoE4), a major risk factor for developing sporadic AD [66] . These results and our data may lead to consider MAMs structural alteration as a common denominator underlying the pathogenesis of AD associated to both sporadic and APP/PS-linked familial AD mutations. In agreement with these data, the proteomic approach revealed potential A␤PP interactors implicated in the regulation of mitochondrial and ER structure (Dnajc11 and atlastin 3 respectively) (Supplementary Table 1 ) [67] [68] [69] . Accordingly, postmortem analysis of human AD brain and those of AD mouse models showed altered expression levels of PACS2 and Sigma1R, thus further establishing deregulated MAMs as a hallmark of AD [70] . Moreover, it is interesting to note that A␤PP processing relies on intact ER-mitochondria crosstalk [21] . Thus, cells deficient of MFN2 show diminished MAM function in terms of lipid metabolism and reduced ␥-secretase activity by approximately 50% [21] . In turn, exposing hippocampal neurons or neuroblastoma cells to A␤ enhances ER-mitochondria contacts [70, 71] . These observations are in favor of a vicious cycle where A␤PP is processed in MAMs, and its derivative catabolites enhance ER-mitochondria communication and function.
We analyzed a second aspect of MAMs function in AD by combining immunoprecipitation and proteomic mass spectrometric analysis to identify molecules that associate with A␤PP and its proteolytic products in MAMs. This approach allows the unbiased and extensive exploration of all possible direct or indirect protein interactors. Nevertheless, we may consider some limitations of the approach used here namely the difficulty to identify interactors of lower expression. This approach failed also to reveal components of ␥-secretase and/or ␤-secretase in MAM proteome analyses. This may be explained by the limitation of immunoprecipitation approach and/or to instable interaction of A␤PP and its cleaving enzymes. Although, the strength of our data is supported by the identification of A␤PP interactors described in previous studies using distinct experimental approaches (i.e., TIM/TOM complex) [8, 43, 44] . Furthermore, we also revealed new protein partners belonging to cellular pathways known to participate to AD pathogenesis. Interestingly, six out of nine of A␤PP and its catabolites interactome related to mitochondrial respiratory chain complexes are components or chaperone of complex I. Previous studies have revealed that A␤ may cause both a selective defect in complex I activity associated with an increase of intracellular reactive oxygen species [72, 73] . We also unraveled an interaction of A␤PP and or its catabolites with the mitochondrial ATP synthase (complex V). Interestingly this enzyme shows reduced activity in AD affected brains [74] .
We revealed the interaction of A␤PP and its catabolites with several proteins implicated in protein synthesis, maturation, folding, processing, and degradation. Several studies have suggested that altered maturation, processing, and degradation of A␤PP holoprotein may drive the availability of A␤PP for A␤ generation [75] [76] [77] [78] . It was also suggested that different PPIases regulate A␤ production, or the toxicity associated with A␤ [79] . Concerning mitochondria, we showed that A␤PP and its catabolites may directly or indirectly interact with mitochondrial presequence protease (PreP, GN: pitrm), a pitrilysin metallopeptidase 1 implicated in the degradation of mitochondrial transit peptides after their cleavage. PreP has been shown to degrade various A␤ peptides thus clearing mitochondrial (A␤) [80, 81] . Accordingly, increased neuronal PreP activity attenuates neuroinflammation and improves mitochondrial and synaptic function in AD mice model [82, 83] .
Finally, we delineate in this study the potential interaction of A␤PP and its catabolites with different proteins related to fatty-acid metabolism. Accordingly, we show increased neutral lipids accumulation in both neuroblastoma and CHO cells expressing APP swe or APP LDN . Neutral lipids accumulation was reported in different AD study models including PS-mutant MEFs, PS double knockout MEFs, fibroblasts from familial AD patients [21] , and more recently fibroblasts exposed to ApoE4 conditioned media [66] . We also revealed that neutral lipids accumulation in our study models is likely linked to A␤ peptides rather to C99 fragment. A more dedicated study is necessary to investigate the molecular mechanisms underlying lipid droplets accumulation in AD. In particular, lipid droplets are found in close proximity with the ER and mitochondria [37, 38] , and the functions of these interactions are still largely unknown. It is, however, noticeable that proteolytic cleavage of A␤PP is tightly regulated by several lipids such as cholesterol and sphingolipids. In turn, A␤ as well as other A␤PP processing products play an essential role in regulating lipid homeostasis [84] . Moreover, in vitro studies have shown that fatty acids may affect A␤ secretion [85] .
In summary, our data extends the previous studies suggesting MAMs as an important contributor to AD pathogenesis. Maintenance and tight regulation of MAM structure and function could be envisioned as potential therapeutic strategies for AD.
